Last reviewed · How we verify
Human rabies immunoglobulins
Human rabies immunoglobulins provide passive immunity by supplying antibodies that neutralize rabies virus and prevent its progression to the central nervous system.
Human rabies immunoglobulins provide passive immunity by supplying antibodies that neutralize rabies virus and prevent its progression to the central nervous system. Used for Post-exposure prophylaxis of rabies in non-immunized or incompletely immunized individuals following potential rabies virus exposure.
At a glance
| Generic name | Human rabies immunoglobulins |
|---|---|
| Also known as | HRIG |
| Sponsor | Sanofi Pasteur, a Sanofi Company |
| Drug class | Immunoglobulin (passive immunization) |
| Target | Rabies virus glycoprotein |
| Modality | Biologic |
| Therapeutic area | Infectious Disease / Immunology |
| Phase | Phase 3 |
Mechanism of action
Rabies immunoglobulins are purified antibodies derived from human plasma of individuals immunized against rabies virus. They bind to and neutralize rabies virus particles, particularly at the site of exposure, and work synergistically with active rabies vaccination to provide rapid immune protection before the virus reaches the central nervous system where it causes fatal encephalitis.
Approved indications
- Post-exposure prophylaxis of rabies in non-immunized or incompletely immunized individuals following potential rabies virus exposure
Common side effects
- Local injection site reactions (pain, erythema, swelling)
- Fever
- Myalgia
- Headache
- Hypersensitivity reactions
Key clinical trials
- A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 With Matrix-M in Combination With R21/Matrix-M (PHASE2)
- A Phase II Trial of a Recombinant Human Anti-Rabies Virus Monoclonal Antibody (PHASE2)
- Washington University WU 409: Immune Responses to Rabies Vaccine. (EARLY_PHASE1)
- Comparison of SYN023 to Human Rabies Immune Globulin in Post Exposure Prophylaxis of Rabies (PHASE2)
- SYN023 With Rabies Vaccine in Healthy Pediatric Subjects (PHASE1)
- Survey of Human Rabies Immune Globulin Safety in Children
- Study of Purified Vero Rabies Vaccine Compared With a Reference Rabies Vaccine as Simulated Rabies Post-Exposure Prophylaxis in Adult and Pediatric Population in Thaïland (PHASE3)
- Study of Purified Vero Rabies Vaccine Compared With a Reference Rabies Vaccine as Simulated Rabies Post-Exposure Prophylaxis in Adults in Thaïland (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |